The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Researchers have found in a new study that Use of GLP-1 receptor agonists before pregnancy was associated with reduced risks ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...

Two new class action complaints, both captioned Robins v. Lemme Inc., were filed in in California Superior Court and the Southern District of New ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications.

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

GLP-1 drugs such as Wegovy, Ozempic, Zepbound and Mounjaro have helped millions of people combat type 2 diabetes and ...

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

“Whether consumers are using GLP-1 medications for weight management or are reducing sugar intake as part of their overall ...

Abalone Bio, an antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, ...